Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
Provided By GlobeNewswire
Last update: Aug 11, 2025
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October -
Read more at globenewswire.com0.4895
+0.04 (+9.34%)
Find more stocks in the Stock Screener
TOVX Latest News and Analysis
